CHPA NDAC nomination
This article was originally published in The Tan Sheet
Executive Summary
CHPA nominates George Goldstein, MD, to represent the industry on FDA's Nonprescription Drugs Advisory Committee, the organization states in a Nov. 28 letter to FDA. The Consumer Healthcare Products Association polled members to identify Goldstein as the "consensus candidate" for industry representative. Goldstein comes to the table with a resume that includes 14 years in private practice as a pediatrician and 15 years with Sterling Drug, according to CHPA. Goldstein served as Chief Medical Officer for Sterling's OTC division, Glenbrook Labs, as well as for the Rx division, Winthrop Labs. FDA announced in November that it was taking nominations for a non-voting industry representative to serve on the committee ("The Tan Sheet" Nov. 21, 2005, In Brief)...You may also be interested in...
NDAC nominations
Nominations for a non-voting industry representative to serve on the Nonprescription Drugs Advisory Committee must be received by FDA no later than Dec. 15, the agency announces in the Nov. 15 Federal Register. Industry organizations interested in participating in the member's selection should notify FDA by letter. The agency will compile a list of nominees by Dec. 15 and will forward the list to participating organizations. A candidate must be selected by participants within 60 days of receipt of the FDA letter. If no candidate is chosen, the FDA commissioner will select the non-voting member, FDA notes. Self-nominations are acceptable and organizations may submit multiple nominations...
Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues
A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand.
Stockwatch: Choppy Waters For Teva And Bausch
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: